LAVA Therapeutics N.V. - Ordinary Shares (NQ:LVTX)

1.740 UNCHANGED

Last Price Updated: 4:00 PM EST, Nov 20, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about LAVA Therapeutics N.V. - Ordinary Shares

< Previous 1 2 3 4 Next >

Why Vallon Pharmaceuticals Shares Are Trading Higher By Over 150%; Here Are 29 Stocks Moving Premarket ↗

December 14, 2022

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 150.9% to $0.6313 in pre-market trading after the company entered into a definitive merger agreement with GRI Bio.

Via Benzinga

LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

December 10, 2022

Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts

From LAVA Therapeutics N.V.

Via GlobeNewswire

Analyst Says This Small Cap Stock Might Be 'Game Changer' In Bispecific T Cell Engagers Space ↗

October 25, 2022

Via Benzinga

Why LAVA Therapeutics Stock Is Up More Than 100% Today ↗

September 26, 2022

LAVA Therapeutics N.V.

Via Benzinga

LAVA Therapeutics Skyrockets After Cancer Agreement With Seagen ↗

September 26, 2022

Via Benzinga

LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial Results

November 16, 2022

From LAVA Therapeutics N.V.

Via GlobeNewswire

LAVA Therapeutics to Present at the Jefferies London Healthcare Conference

November 03, 2022

From LAVA Therapeutics N.V.

Via GlobeNewswire

LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition

November 03, 2022

From LAVA Therapeutics N.V.

Via GlobeNewswire

LAVA Therapeutics Highlights Encouraging Clinical Updates on Lead Cancer Program ↗

June 17, 2022

Via Benzinga

LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial Officer

November 01, 2022

From LAVA Therapeutics N.V.

Via GlobeNewswire

Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2022 ↗

October 25, 2022

Upgrades

Via Benzinga

LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting

October 07, 2022

From LAVA Therapeutics N.V.

Via GlobeNewswire

Snap To Surge Around 20%? Here Are 5 Other Price Target Changes For Tuesday ↗

September 27, 2022

Piper Sandler raised Snap Inc. (NYSE: SNAP) price target from $11 to $12. Piper Sandler analyst Thomas Champion maintained the stock with a Neutral. Snap shares fell 1.4% to close at $10.18 on Monday.

Via Benzinga

Nasdaq Turns Lower; Crude Oil Drops Sharply ↗

September 26, 2022

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite turning negative on Monday.

Via Benzinga

LAVA Therapeutics (NASDAQ: LVTX) Enters into Global Licensing Agreement with Seagen (NASDAQ: SGEN) to Develop and Commercialize LAVA-1223

September 26, 2022

LAVA Therapeutics N.V. (NASDAQ: LVTX) is engaged as a clinical-stage oncology company, which is focused on the research and development

Via Spotlight Growth

Why Aridis Pharmaceuticals Shares Plunged Around 30%; Here Are 81 Biggest Movers From Yesterday ↗

September 27, 2022

Gainers

Via Benzinga

Why LAVA Therapeutics Shares Are Trading Higher By 97%, Here Are 49 Stocks Moving In Monday's Mid-Day Session ↗

September 26, 2022

Gainers

Via Benzinga

Dow Drops Over 100 Points; Crude Oil Rises Over 1% ↗

September 26, 2022

U.S. stocks traded mixed midway through trading, with the Dow Jones dropping more than 100 points on Monday.

Via Benzinga

What Is Going on With Lava Therapeutics (LVTX) Stock Today? ↗

September 26, 2022

Lava Therapeutics (LVTX) stock is rocketing higher on Monday as investors react to an exclusive global license agreement with Seagen (SGEN).

Via InvestorPlace

US Stocks Mostly Higher; Nasdaq Rises Over 100 Points ↗

September 26, 2022

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday.

Via Benzinga

Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

September 26, 2022

From Seagen Inc.

Via Business Wire

5 Value Stocks To Watch In The Healthcare Sector ↗

June 06, 2022

The Meaning Behind Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 15, 2022 ↗

September 15, 2022

Upgrades

Via Benzinga

The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More ↗

May 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Boeing, PriceSmart And 80 Biggest Movers From Yesterday ↗

July 13, 2022

Gainers Sharps Compliance Corp. (NASDAQ: SMED) shares jumped 196.1% to close at $8.44 on Tuesday after the company it will be acquired by an affiliate of Aurora Capital Partners for $8.75 per share.

Via Benzinga

LAVA Therapeutics Shares Interim LAVA-051 Data From Early-Stage Cancer Trial ↗

March 07, 2022

LAVA Therapeutics NV (NASDAQ: LVTX) announced initial data from its first clinical study with LAVA-051. The presentation will include data from the first...

Via Benzinga

52 Biggest Movers From Yesterday ↗

February 15, 2022

Gainers BioDelivery Sciences International, Inc. (NASDAQ: BDSI) shares climbed 52.8% to close at $5.56 on Monday. Collegium Pharmaceutical will acquire BioDelivery Sciences...

Via Benzinga

The Daily Biotech Pulse: ImmunityBio Reports Positive Readout, Valneva Starts Late-Stage Chikungunya Vaccine Study, Sio Gene Shelves Parkinson's Program ↗

February 01, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

40 Biggest Movers From Friday ↗

January 03, 2022

Gainers Nutriband Inc. (NASDAQ: NTRB) shares climbed 157.8% to close at $10.08 on Friday after the company announced the Korean Intellectual Property Office has fully issued its...

Via Benzinga

The Daily Biotech Pulse: Moderna's Booster Shot Gets FDA Panel Backing, Decision Day For Avadel, Silence Therapeutics Strikes Licensing Deal, MiNK IPO ↗

October 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Adcom Recommends Approval Of Moderna's COVID-19 Vaccine Booster Shot For...

Via Benzinga

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.